- Associated Press - Tuesday, January 21, 2014

STRONG QUARTER: Johnson & Johnson’s fourth-quarter net income jumped 19 percent to $3.52 billion. Revenue rose 4.5 percent to $18.36 billion.

THE DRIVERS: Sales of key prescription drugs and three new ones boosted that business by 12 percent, the consumer health business rebounded as three-quarters of J&J;’s recalled nonprescription medicines are now back in stores, and it got a $707 million tax benefit from writing off money-losing subsidiary Scios.

THE FORECAST: J&J; expects 2014 earnings per share of $5.75 to $5.85, just below Wall Street’s consensus. Some analysts think it can’t sustain its recent prescription drug sales growth rate.


Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide